Transition Bio Analysis: $77M Raised
What is Transition Bio?
Condensate drug discovery platform leveraging microfluidics
Location
Cambridge, United States
Employees
11-50
Founded
2020
Product Features & Capabilities
- Condensate drug discovery platform
- Droplet microfluidics technology
- Cellular imaging solutions
- Machine learning optimization for drug discovery
Use Cases
Analyze chemical interactions in condensate systems; Develop small-molecule inhibitors for cancer treatment; Optimize drug candidates using AI; Conduct research in collaboration with academic labs; Present research findings at scientific conferences
Other Considerations
Closed $50 million Series A financing; Presented research at AACR-NCI-EORTC 2025; Leadership team includes experienced executives from biotech
Find more companies like Transition Bio
See something that needs updating? Suggest edits to this profile.
